Endpoints News

FDA approves AstraZeneca's blood pressure pill		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

Mon T W Th F

18 May, 2026

LGBTQ+ diversity drives innovation in biopharma — but transgender and non-binary professionals face rising challenges. Endpoints is going live with our fourth annual special report celebrating the honorees giving voice and visibility while forging ahead across life sciences. Join us.

news

Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3

AstraZeneca's blood pressure pill approved, but competition could be around the corner

Updated: CDER chief Høeg, skeptic of vaccines and antidepressants, is fired in high-level FDA shakeup

•

Post-Hoc Live: Marty Makary's FDA downfall and legacy

May 20

11:00 am ET

Application of Simple Western to analysis of antibody target affinity and specificity

sponsored by Bio-Techne

ASCO is about to deliver some make-or-break cancer data. Join us to figure out which pipeline bets will pay off. Get your spot now.

ENDPOINTS PHARMA

Are pharma megadeals dead? Smaller targets take priority amid hunt for blockbusters

•

M&A isn’t just for big pharma. A diverse group of mid-size companies are stepping up dealmaking

Amgen expands crackdown on what it says is misuse of 340B program

Supreme Court preserves mail access for abortion pill

in case you missed it

Candel reports prostate cancer drug's long-term data ahead of FDA filing

Peer Review

Andrea Pfeifer ends 23-year reign at AC Immune; Acadia's top R&D exec announces retirement

News Briefing

Aardvark's next move after clinical hold; Alumis' verdict on Acelyrin asset

A Zillow-like marketplace for abandoned gene therapies goes live

WHO says Ebola outbreak in DRC and Uganda is ‘emergency’ of international concern

Activist Elliott builds big stake in life science tools supplier Bio-Rad

In case you missed it, we had a couple of insightful stories on how pharma M&A is shaping up. Kyle LaHucik has a piece on how nontraditional buyers are getting into the action, while Max Bayer has a story that raises the question: are megadeals are still a thing?

Reynald Castaneda

Deputy Editor, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com